Skip to content
Sign in
↑Part of: FDA approves Rasonque after trial shows longer survival in pancreatic cancer
Health · Europe

Incyte reports pancreatic cancer drug responses in Phase 1 study

Incyte said its drug, combined with chemotherapy, produced tumor responses in some patients with pancreatic cancer. STAT reported an 81% response rate and said Incyte viewed the results as supporting its decision to advance the treatment to a late-stage trial.

AI-assisted synthesis · Based on 3 outlets' reporting · Article text read from 1 of 3 outletsHow it's made

View timeline · 5 entries
3 outletsLatest reporting 4 min read
Coverage: Too few ratedL 0 · C 1 · R 0 · 2 unrated
Updat3 graphic: Incyte
Updat3 graphic

What happened

Key facts

  • Incyte reported Phase 1 results for its pancreatic cancer drug at ESMO.
  • The company said the drug combined with chemotherapy produced lasting tumor responses in certain patients.
  • STAT reported an 81% response rate for the pancreatic cancer drug.
  • Incyte said the results supported its prior decision to advance the treatment into a late-stage clinical trial.
  • The drug targets a KRAS mutation; STAT reported that about 40% of pancreatic tumors involve the mutation targeted by the drug.
  • The article says Revolution Medicines’ Rasonque was approved earlier in 2026 and that companies including Incyte, Revolution Medicines, Verastem, and Hengrui are developing drugs targeting specific RAS-family mutations.

The brief

Incyte said its pancreatic cancer drug, when combined with chemotherapy, produced lasting tumor responses in some patients in a Phase 1 study. STAT reported an 81% response rate and said the company considers the findings support for its earlier decision to move the treatment into a late-stage clinical trial. Incyte presented the results at ESMO, according to STAT.

The account describes the treatment as a targeted drug used alongside chemotherapy, but does not provide the number of patients, the duration of responses or further detail on how the response rate was calculated. The 81% figure is reported by STAT; the outlet’s excerpt does not give a trial-wide breakdown or additional efficacy measures.

STAT reported that the drug targets a KRAS mutation and that about 40% of pancreatic tumors involve the mutation targeted by the treatment. The outlet places Incyte’s study in a field where companies are developing medicines aimed at particular mutations within the broader RAS family. It names Incyte, Revolution Medicines, Verastem and Hengrui among those companies.

The competitive context includes Revolution Medicines’ pancreatic cancer drug Rasonque, which STAT says was approved earlier in 2026. Fierce Biotech’s headline separately characterizes Incyte as viewing its position as “neck and neck” with Revolution Medicines in a KRAS G12D pancreatic cancer race.

That headline does not provide trial figures or evidence for comparing the treatments, so it does not establish how their results compare. Incyte’s stated next step is already reflected in its decision to advance the treatment to a late-stage trial, which the company said the Phase 1 findings support.

The account does not name a future trial start date or report additional trial details. Its description of lasting responses does not specify how long they lasted. The report therefore presents an early clinical result and Incyte’s rationale for moving the drug forward, alongside a competitive landscape that includes an approved medicine and other mutation-focused programs.

The response rate and the company’s assessment are the specific evidence reported here; the account does not provide comparative outcomes for the competing treatments.

Why it matters

  • Advancing the drug to a late-stage trial gives Incyte a chance to test in a larger study whether the tumor responses seen in Phase 1 translate into meaningful patient benefit. For patients with the targeted KRAS mutation, it could eventually add a treatment option, but the early results do not change current care or establish that the drug works.

What to watch next

  • Whether Incyte provides further details on the late-stage clinical trial it has decided to pursue.
  • Whether Incyte reports additional information about the duration of the tumor responses.
  • How Incyte’s KRAS-targeted program is positioned alongside Revolution Medicines’ Rasonque and other mutation-focused programs.

How it's being covered

Coverage analysisShow details
3 source articles · 3 unique outlets
Outlet political mix: Too few rated· 1 Center · 2 unrated
Where the outlets are based: Unknown 100%
Outlet political mix
Too few rated
Left
Center
Right
0 outlets
1 outlet
0 outlets
The marker shows coverage balance: each unique outlet counts once. 2 unrated outlets are not included.
Geography
Where the outlets covering this story are based.
3 unique outlets
Coverage imbalance
  • Coverage is currently concentrated among outlets based in Unknown (3 of 3 geographically-identified sources).
How we measure coverage

How outlets' accounts compare

Updat3 does not yet have enough full reports to compare how outlets framed this story.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. Work published in 2013 by researchers led by Kevan Shokat described a strategy for targeting the KRAS G12C variant, helping renew efforts to develop mutation-specific drugs.
    Background · from our historical context
  2. The FDA approved sotorasib, the first KRAS G12C inhibitor, for certain patients with lung cancer.
    Background · compiled and fact-checked by Updat3
  3. Amplia Therapeutics began the Phase 2 stage of the ACCENT trial of narmafotinib with chemotherapy in advanced pancreatic cancer.
    Background · compiled and fact-checked by Updat3
  4. Incyte began a Phase 1 study of its KRAS G12D inhibitor, INCB161734.
    Background · compiled and fact-checked by Updat3
  5. Revolution Medicines received approval for Rasonque.
    Background · compiled and fact-checked by Updat3

How we got here

Pancreatic cancer has long been difficult to treat because it is often diagnosed after it has spread, and many tumors do not respond durably to available therapies. Pancreatic ductal adenocarcinoma is the most common form of the disease.

For patients whose cancer cannot be removed surgically, treatment has generally relied on chemotherapy, including combinations such as FOLFIRINOX or gemcitabine with nab-paclitaxel. These regimens can slow disease or shrink tumors for some patients, but their benefits are limited for many, creating a need for treatments aimed at molecular features of the cancer.

Original sources

3 articles from 3 outlets

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.